PF-07038124治疗特应性皮炎与斑块状银屑病的随机临床试验
这项2a期随机双盲试验在4国34个中心纳入104例轻中度特应性皮炎(AD)或斑块状银屑病患者,1:1随机接受PF-07038124 0.01%软膏或赋形剂每日1次共6周。第6周时,AD组EASI改善显著优于赋形剂,银屑病组PASI改善也显著优于赋形剂,且未报告应用部位反应。
要点
- PF-07038124 0.01%软膏每日1次治疗6周,对轻中度AD和斑块状银屑病均优于赋形剂。
- AD患者EASI最小二乘均值变化为-74.9%对-35.5%,差异-39.4%(90%CI -58.8%至-20.1%,P<.001)。
- 银屑病患者PASI变化为-4.8对0.1,差异-4.9(90%CI -7.0至-2.8,P<.001),且无应用部位反应。
核心结论
- PF-07038124 0.01%软膏每日1次治疗6周耐受良好,在轻中度AD和斑块状银屑病患者中疗效优于赋形剂。
研究设计与样本
- 2a期随机双盲临床试验,2020年12月21日至2021年8月18日在4国34个中心开展,共随机104例18-70岁轻中度AD或斑块状银屑病患者。
- 患者按1:1随机接受PF-07038124 0.01%软膏或赋形剂每日1次,治疗6周。
主要发现
- AD患者第6周EASI最小二乘均值较基线变化:PF-07038124组-74.9%,赋形剂组-35.5%,差异-39.4%(90%CI -58.8%至-20.1%,P<.001)。
- 银屑病患者第6周PASI较基线变化:PF-07038124组-4.8,赋形剂组0.1,差异-4.9(90%CI -7.0至-2.8,P<.001)。
- 治疗中出现不良事件的患者数在AD组(PF-07038124 9例[25.0%] vs 赋形剂9例[26.5%])和银屑病组(3例[17.6%] vs 6例[35.3%])治疗间相当。
- PF-07038124治疗未报告应用部位反应。
关键数值与推荐
- 主要终点为第6周AD患者EASI总分和银屑病患者PASI评分较基线的百分比变化。
- AD入组条件为皮损面积占体表面积5%-20%,银屑病为5%-15%。
临床怎么用
- 对于轻中度AD和斑块状银屑病,PF-07038124 0.01%软膏每日1次可作为潜在外用治疗选择,但需进一步验证。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Atopic dermatitis (AD) and plaque psoriasis are inflammatory skin diseases with unmet need for effective topical treatments with few application site reactions. OBJECTIVE: To assess the efficacy and safety of the topical phosphodiesterase 4 inhibitor PF-07038124 in patients with AD and plaque psoriasis. DESIGN, SETTING, AND PARTICIPANTS: This phase 2a, randomized, double-blind clinical trial was conducted from December 21, 2020, to August 18, 2021, at 34 sites across 4 countries. Eligible patients (aged 18-70 years) had mild to moderate AD (covering 5%-20% body surface area) or plaque psoriasis (covering 5%-15% body surface area). Data were analyzed until December 15, 2021. INTERVENTIONS: Patients were randomized (1:1) to PF-07038124, 0.01%, topical ointment or vehicle once daily for 6 weeks. MAIN OUTCOMES AND MEASURES: The primary end point was the percent change from baseline (CFB) in the Eczema Area and Severity Index (EASI) total score among patients with AD and in the Psoriasis Area and Severity Index (PASI) score among patients with plaque psoriasis at week 6. Safety measures included treatment-emergent adverse events, including application site reactions. RESULTS: Overall, 104 patients were randomized (mean [SD] age, 43.0 [15.4] years; 55 [52.9%] women; 4 [3.8%] Asian, 13 [12.5%] Black, and 87 [83.7%] White), including 70 with AD (41 women [58.6%]; mean [SD] ages, 41.4 [16.6] years in the PF-07038124 group and 36.1 [13.9] years in the vehicle group) and 34 with plaque psoriasis (20 men [58.8%]; mean [SD] ages, 51.8 [12.3] years in the PF-07038124 group and 51.2 [10.8] years in the vehicle group). Baseline characteristics were generally balanced. At week 6, the PF-07038124 groups showed significantly greater improvements compared with vehicle groups in EASI (least-squares mean CFB, -74.9% vs -35.5%; difference, -39.4% [90% CI, -58.8% to -20.1%]; P < .001) and PASI scores (CFB, -4.8 vs 0.1; difference, -4.9 [90% CI, -7.0 to -2.8]; P < .001). The number of patients with treatment-emergent adverse events was comparable between treatment groups in patients with AD (PF-07038124, 9 [25.0%]; vehicle, 9 [26.5%]) and plaque psoriasis (PF-07038124, 3 [17.6%]; vehicle, 6 [35.3%]). There were no application site reactions with PF-07038124 treatment. CONCLUSIONS AND RELEVANCE: Topical PF-07038124 was well tolerated and demonstrated superior efficacy compared with vehicle in patients with mild to moderate AD and plaque psoriasis. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04664153.
引用
- Eichenfield LF, Tarabar S, Forman S, et al. Efficacy and Safety of PF-07038124 in Patients With Atopic Dermatitis and Plaque Psoriasis: A Randomized Clinical Trial. JAMA Dermatol. 2024. PMID: 38117526. doi:10.1001/jamadermatol.2023.4990
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。